Nasal route: An alternative approach for antiemetic drug delivery

Expert Opinion on Drug Delivery

Volumn 8, Issue 11, 2011, Pages 1439-1453

  Ozsoy, Yildiz ^a   Gngör, Sevgi ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Antiemetic drugs; Dimenhydrinate; Domperidone; Granisetron; Metoclopramide; Nasal in situ gels; Nasal microspheres; Nasal route; Nasal solutions; Ondansetron; Promethazine

Indexed keywords

ALGINIC ACID; CARBOMER; CHITOSAN; CIPROFLOXACIN; CYANOCOBALAMIN; DESMOPRESSIN ACETATE; DICHLOROMETHANE; DIMENHYDRINATE; DOMPERIDONE; GELLAN; GRANISETRON; HYDROXYETHYLCELLULOSE; HYDROXYETHYLMETHYLCELLULOSE; HYDROXYPROPYLCELLULOSE; MACROGOL 400; METHYLCELLULOSE; METOCLOPRAMIDE; MICROSPHERE; NAFARELIN ACETATE; ONDANSETRON; POLOXAMER; POLYARGININE; POLYMER; POLYVINYL ALCOHOL; PROMETHAZINE; PROTAMINE SULFATE; SALCATONIN;

CHEMICAL STRUCTURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; FIRST PASS EFFECT; GEL; HUMAN; LIPOPHILICITY; MOLECULAR WEIGHT; MUCOADHESION; NONHUMAN; NOSE MUCOSA; OSMOLARITY; PARTICLE SIZE; PATIENT COMPLIANCE; PH; QUALITY OF LIFE; REVIEW; VISCOSITY;

ABSORPTION; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIEMETICS; BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; HUMANS; MEDICATION ADHERENCE; NASAL MUCOSA;

EID: 80054806088     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.607437     Document Type: Review

References (111)

1. Follet CV, Farinotti R, Palmer JL. Physiology of chemotherapy-induced emesis and antiemetic therapy: predictive models for evaluation of new compounds. Drugs 1997;53:206-34 (Pubitemid 27073113)
2. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs 1998;55:173-89 (Pubitemid 28081623)
3. Harrington RA, Hamilton CW, Brogden RN, et al. Metoclopramide an updated review of its pharmacological properties and clinical use. Drugs 1983;25:451-94 (Pubitemid 13130833)
4. Pasricha PJ. Prokinetic agents, antiemetics, and agents used in irritable bowel syndrome. Chapter 38. In: Hardman JG, Limbird LE, Gilman AG. editors. Goodman & Gilman's the pharmacological basis of therapeutics. 10th edition. New York; McGraw-Hill 2001. p. 1021-36
5. Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today 2002;7:967-75 (Pubitemid 35286901)
6. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 2001;53:3-21 (Pubitemid 32140298)
7. Behl CR, Pimplaskar HK, Sileno AP, et al. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev 1998;29:89-116 (Pubitemid 28044088)
8. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003;87:187-98 (Pubitemid 36255456)
9. Cornaz AL, Buri P. Nasal mucosa as an absorption barrier. Eur J Pharm Biopharm 1994;40:261-70 (Pubitemid 24342909)
10. Jones N. The Nose and paranasal sinuses physiology and anatomy. Adv Drug Deliv Rev 2001;51:5-19 (Pubitemid 32763069)
11. Ozsoy Y. Particulate carriers for nasal administration. In: Kumar MNVR. editor. Handbook of particulate drug delivery. California; (Volume 2) American Scientific Publisher; 2008. p. 143-92
12. Pires A, Fortuna A, Alver G, et al. Intranasal drug delivery: how, why and what for? J Pharm Sci 2009;12:288-311
13. Lansey AB, Martin GP. Nasal drug delivery. Chapter 9. In: Hillery AM, Lloyd AW, Swarbrick J. editors. Drug delivery and targeting for pharmacists and pharmaceutical scientists. New York; Taylor & Francis; 2001. p. 215-43
14. Verdugo P. Goblet cells secretion and mucogenesis. Annu Rev Physiol 1990;52:157-76 (Pubitemid 20103532)
15. Lethem MI. The role of tracheobronchial mucus in drug administration to the airways. Adv Drug Deliv Rev 1993;11:271-98 (Pubitemid 23302849)
16. Schipper NGM, Verhoef JC, Merkus FWHM. The nasal mucociliary clearance of relevance to nasal drug delivery. Pharm Res 1991;8:807-14
17. Martin E, Schipper NGM, Verhoef JC, et al. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 1998;29:13-38
18. Ozer Y. Alternative applications for drug delivery: nasal and pulmonary routes. In: Mozafari MR. editor. Nanomaterials and nanosystems for biomedical applications. Dordrecht; Springer; 2007. p. 99-12
19. Karla PK, Kwatra D, Gaudana R, et al. Nasal drug delivery. In: Rathbone MJ, Hadgraft J, Roberts MS, Lane ME. editors. Modified-release drug delivery technology. 2nd edition. (Volume 2) New York; Informa Healthcare 2008. p. 427-50
20. Bhise SB, Yadav AV. Bioavailability of intranasal drug delivery. Asian J Pharm 2008;2:201-15
21. Jadhav KR, Gambhire MN, Shaikh IM, et al. Nasal drug delivery system-factors affecting and applications. Curr Drug Ther 2007;2:27-38 (Pubitemid 46723136)
22. Donovan MD, Huang Y. Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption. Adv Drug Deliv Rev 1998;29:147-55 (Pubitemid 28044091)
23. Quraishi MS, Jones NS, Mason JDT. The nasal delivery of drugs. Clin Otolaryngol 1997;22:289-01
24. Hussain A, Hamadi S, Kagashima M, et al. Does increasing the lipophilicity of peptides enhance their nasal absorption? J Pharm Sci 1991;80:1180-1
25. Sanders P, Washington N, Frier M, et al. The deposition of solution-based and suspension-based aerosols from metered dose inhalers in healthy subjects and asthmatic patients. S.T.P. Pharm Sci 1997;7:300-6
26. Hussain AA. Intranasal drug delivery. Adv Drug Deliv Rev 1998;2:39-49 (Pubitemid 28044085)
27. Kublik H, Vidgren MT. Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 1998;29:157-77 (Pubitemid 28044092)
28. Gizurarson S. The relevance of nasal physiology to the design of drug absorption studies. Adv Drug Deliv Rev 1993;11:329-47 (Pubitemid 23302851)
29. Washington N, Washington C, Wilson CG. Physiological pharmaceutics: barriers to drug absorption, 2nd edition, Taylor & Francis, New York; 2001, p. 199-220
30. Sciarra JJ. Aerosols. Chapter 95. In: Gennaro AR. editor. Remington: the Science and practice of pharmacy. 19th edition. Pennsylvania; Mack Publishing Co 1995. p. 1676-92
31. Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007;337:1-24 (Pubitemid 46756063)
32. Ungell AL, Andreasson A, Lundin K, et al. Effects of enzymatic inhibition and increased paracellular shunting on the transport of vasopressin analogues in the rat. J Pharm Sci 1992;81:640-5 (Pubitemid 23006788)
33. Corbo DC, Liu JC, Chien YW. Drug absorption through mucosal membranes. Effect of mucosal route and penetrant hydrophilicity. Pharm Res 1989;6:848-52
34. Ingemann M, Frokjaer S, Hovgaard L, et al. Peptide and protein drug delivery systems for non-parenteral routes of administration. Chapter 10. In: Frokjaer S, Hovgaard L. editors. Pharmaceutical formulation development of peptides and proteins. Philadelphia; Taylor & Francis 2000. p. 189-205
35. McMartin C, Hutchinson LE, Hyde R, et al. Analysis of structural requirements for the absorbtion of drugs and macromolecules from the nasal cavity. J Pharm Sci 1987;76:535-40
36. Brooking J, Davis SS, Illum L. Transport of nanoparticles across the rat nasal mucosa. J Drug Target 2001;9:267-79 (Pubitemid 32776362)
37. Sambhaji S, Pisal AR, Paradkar KR, et al. Pluronic gels for nasal delivery of Vitamin B12 Part I: preformulation study. Int J Pharm 2004;270:37-45
38. Ozsoy Y, Tuncel T, Can A, et al. In vivo studies on the nasal preparations of ciprofloxacin hydrochloride. Pharmazie 2000;55:607-9
39. Ugwoke MI, Sam E, Van Den Mooter G, et al. Nasal mucoadhesive delivery systems of the anti-parkinsonian drug, apomorphine: influence of drug-loading on in vitro and in vivo release in rabbits. Int J Pharm 1999;181:125-38 (Pubitemid 29199894)
40. Callens C, Pringels E, Remon JP. Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability. Int J Pharm 2003;250:415-22 (Pubitemid 36084364)
41. Callens C, Ceulemans J, Ludwig A, et al. Rheological study on mucoadhesivity of some nasal powder formulations. Eur J Pharm Biopharm 2003;55:323-8 (Pubitemid 36561559)
42. Illum L, Watts P, Fisher AN, et al. Intranasal delivery of morphine. J Pharmacol Exp Ther 2002;301:391-400 (Pubitemid 34250318)
43. Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular weight drugs. Molecules 2009;14:3754-79
44. Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 2003;42:1107-28 (Pubitemid 37357648)
45. Behl CR, Pimplaskar HK, Sileno AP, et al. Optimization of systemic nasal drug delivery with pharmaceutical excipients. Adv Drug Deliv Rev 1998;29:117-33 (Pubitemid 28044089)
46. Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci 2004;26:137-42 (Pubitemid 39012580)
47. Merkus FWHM, Verhoef JC, Marttin E, et al. Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev 1999;36:41-57 (Pubitemid 29074476)
48. Yamamoto A, Morita T, Hashida M, et al. Effect of absorption promoters on the nasal absorption of drugs with various molecular weights. Int J Pharm 1993;93:91-9 (Pubitemid 23181286)
49. Pereswetoff-Morath L. Microspheres as nasal drug delivery systems. Adv Drug Deliv Rev 1998;29:185-94 (Pubitemid 28044094)
50. Abd El-Hameed MD, Kellaway IW. Preparation and in vitro characterisation of mucoadhesive polymeric microspheres as intra-nasal delivery systems. Eur J Pharm Biopharm 1997;44:53-60 (Pubitemid 28298775)
51. McDonough J, Dixon H, Ladika M. Nasal delivery of micro- and nano-encapsulated drugs. Chapter 8. In: Kulkarni VS. editor. Handbook of non-invasive drug delivery systems. 2010. Burlington; Elsevier, p. 193-208
52. Ugwoke MI, Agu RU, Verbeke N, et al. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv Drug Deliv Rev 2005;57:1640-65 (Pubitemid 41443473)
53. Fransen N, Bjork E, Nystrom C. Development and characterisation of interactive mixtures with a fine-particulate mucoadhesive carrier for nasal drug delivery. Eur J Pharm Biopharm 2007;67:370-6 (Pubitemid 47211914)
54. Sweetman SC. Martindale, the complete drug reference. 35th edition. Pharmaceutical Press; London; 2007. p. 1526-602
55. Kraut L, Fauser AA. Anti-emetics for cancer chemotherapy induced emesis. Drugs 2001;61:1553-62
56. The Merck Index. 13th edition. Merck & Co., Inc; New Jersey 2001
57. Bateman DN, Kahn C, Davies DS. The pharmacokinetics of metoclopramide in man with observations in the dog. J Clin Pharm 1980;9:371-7 (Pubitemid 10067058)
58. Comier M, Chao ST, Grupta SK, et al. Effect of transdermal iontophoresis codelivery of hydrocortisone on metoclopramide pharmacokinetics and skin-induced reactions in human subjects. J Pharm Sci 1999;88:1030-5 (Pubitemid 29480595)
59. Aktar B. Studies on the enhancement of in vitro penetration of metoclopramide hydrochloride with terpenes, Istanbul University, Institute of Health Science, Department of Pharmaceutical Technology, Master of Science Thesis. Istanbul: 2009
60. Zaki NM, Awad GA, Nahaed D, et al. Enhanced bioavailability of metoclopramide HCI by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci 2002;32:295-307
61. Dias RJ, Mali KK, Shinde JV, et al. Formulation and evaluation of thermoreversible mucoadhesive nasal gels of metoclopramide. Latin Am J Pharm 2010;29:354-61
62. Mahajan HS, Gattani S. In situ gels of metoclopramide hydrochloride for intranasal delivery: In vitro evaluation and in vivo pharmacokinetic study in rabbits. Drug Deliv 2010;17:19-27
63. Sheth P, Zia H, Needham T. Development of a nasal formulation containing ketorolac tromethamine and metoclopramide hydrochloride. S.T.P. Pharm Sci 2002;12:39-44 (Pubitemid 34093347)
64. Zaki NM, Awad GAS, Mortoda ND, et al. Rapid-onset intranasal delivery of metoclopramide hydrochloride part I. Influence of formulation variables on drug absorption in anesthetized rats. Int J Pharm 2006;327:89-96 (Pubitemid 44755247)
65. Zaki NM, Mortada ND, Awed GAS, et al. Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: safety of various absorption enhancers and pharmacokinetic evaluation. Int J Pharm 2006;327:97-103 (Pubitemid 44755246)
66. Bortoli A, Prada A, Confalonieri M, et al. Efficacy and tolerability of metoclopramide nasal spray in the symptomatic therapy of functional dyspepsia. Curr Ther Res 1994;55:1192-200 (Pubitemid 24333547)
67. Vivien N, Buri P, Balant L, et al. Nasal absorption of metoclopramide administered to man. Eur J Pharm Biopharm 1994;40:228-31 (Pubitemid 24276313)
68. Tas C, Kose Ozkan C, Savaser A, et al. Nasal absorption of metoclopramide from different Carbopol 981 based formulations: in vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm 2006;64:246-54 (Pubitemid 44308522)
69. Tas C, Kose Ozkan C, Savaser A, et al. Nasal absorption of metoclopramide from different dosage forms: in vitro, ex vivo, and in vivo evaluation. Drug Deliv 2009;16:167-75
70. Conte U, Conti B, Giunchedi P, et al. Spray dried polylactide microsphere preparation: Influence of the technological parameters. Drug Dev Ind Pharm 1994;20:235-58 (Pubitemid 24095369)
71. Gavini E, Rassu G, Sonna V, et al. Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: in-vitro/ex-vivo studies. J Pharm Pharmacol 2005;57:287-94 (Pubitemid 40314426)
72. Gavini E, Rassu G, Muzzarelli C, et al. Spray-dried microspheres based on methylpyrrolidone chitosan as new carrier for nasal administration of metoclopramide. Eur J Pharm Biopharm 2008;68:245-52
73. Mahajan HS, Gattani SG. Gellan gum microparticles of metoclopramide hydrochloride for intranasal delivery: Development and evaluation. Chem Pharm Bull (Tokyo) 2009;57:388-92
74. Sharma N, Sharma A, Sharma PK, et al. Mucoadhesive thermoreversible nasal delivery system. J Pharm Res 2010;3:991-7
75. Markus FWHM, Schipper NGM, Hermens WAJJ, et al. Absorption enhancers in nasal drug delivery: efficacy and safety. J Control Release 1993;24:201-76
76. Marttin E, Verhof JC, Romejin SG, et al. Effects of nasal absorption enhancers on rat nasal epithelium in vivo: release of marker compounds in the nasal cavity. Pharm Res 1995;12:1151-7
77. Florea BI, Cassara ML, Junginger HE, et al. Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J Control Release 2003;87:131-8 (Pubitemid 36255450)
78. Gurcan D, Okyar A, Ozbek B, et al. Nasal Administration of ciprofloxacin HCl loaded chitosan microspheres: in vitro and in vivo. Eval Acta Pharm Sci 2010;52:5-18
79. Illum L, Watts P, Fisher AN, et al. Novel chitosan-based delivery systems for the nasal administration of a LHRH-analogue S.T.P. Pharm Sci 2000;10:89-94 (Pubitemid 30126791)
80. Soane RJ, Hinchcliffe M, Davis SS, et al. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 2001;217:183-91 (Pubitemid 32268644)
81. Artursson P, Lindmark T, Davis SS, et al. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2.). Pharm Res 1994;11:1358-61 (Pubitemid 24287420)
82. Schipper NGM, Olsson S, Hoogstraate JA, et al. Chitosans as absorption enhancers for poorly absorbable drugs: 2. Mechanism of absorption enhancement. Pharm Res 1997;14:923-9 (Pubitemid 27326989)
83. Lehr CM, Bouwstra JA, Schacht EH, et al. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 1992;78:43-8
84. Henriksen I, Green KL, Smart JD, et al. Bioadhesion of hydrated chitosans: An in vitro and in vivo study. Int J Pharm 1996;145:231-40 (Pubitemid 27063004)
85. Park K, Robinson JR. Bioadhesive polymers as platforms for oral controlled drug delivery: method to study bioadhesion. Int J Pharm 1984;198:107-27 (Pubitemid 14144031)
86. Gombotz WR, Wee SF. Protein release from alginate matrices. Adv Drug Deliv Rev 1998;31:267-85 (Pubitemid 28191869)
87. Scarantino CW, Ornitz RD, Hoffman LG. Radiation induced emesis: Effects of ondansetron. Semin Oncol 1992;19:38-43 (Pubitemid 23047127)
88. Eilde MI, Markham A. Ondansetron: a review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996;52:773-94 (Pubitemid 26382192)
89. Roila F, Del Fevero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 1995;29:95-109
90. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002;54:1295-310 (Pubitemid 35284254)
91. Swain K, Pattnaik S, Sahu SC, et al. Drug in adhesive type transdermal matrix system of ondansetron hydrochloride: optimisation of permeation pattern using response surface methodology. J Drug Target 2010;18:106-14
92. Can AS. Developing ondansetron hydrochlorides topical formulations and to examine their percutaneous absorptions, Istanbul University, Institute of Health Sciences, Department of Pharmaceutical Technology, Master of Science Thesis. Istanbul: 2011
93. Ozdin D. Investigation of transdermal iontophoretic delivery of ondansetron hydrochloride. Istanbul University, Institute of Health Science, Department of Pharmaceutical Technology, Master of Science Thesis. Istanbul: 2011
94. Krishnaiah YS, Bhaskar P, Satyanarayana V. Effect of PEG6000 on the in vitro and in vivo transdermal permeation of ondansetron hydrochloride from EVA1802 membranes. Pharm Dev Technol 2009;14:53-64
95. Hussain AA, Dakkuri A, Itoh S. Nasal absorption of ondansetron in rats: an alternative route of drug delivery. Cancer Chemother Pharmacol 2000;45:432-4 (Pubitemid 30217170)
96. Cho E, Gwak H, Chun I. Formulation and evaluation of ondansetron nasal delivery systems. Int J Pharm 2008;349:101-7 (Pubitemid 350299693)
97. Bhalarao AV, Lonkar SL, Deshkar SS, et al. Nasal mucoadhesive in situ gel of ondansetron hydrochloride. Indian J Pharm Sci 2009;71:711-13
98. Gungor S, Okyar A, Erturk Toker S, et al. Ondansetron- loaded chitosan microspheres for nasal antiemetic drug delivery: an alternative approach to oral and parenteral routes. Drug Dev Ind Pharm 2010;36:806-13
99. Gungor S, Okyar A, Erturk Toker S, et al. Ondansetron-loaded biodegradable microspheres as a nasal sustained delivery system: in vitro/in vivo studies. Pharm Dev Technol 2010;15:258-65
100. Mahajan HS, Guttani SG. Nasal administration of ondansetron using a novel microspheres delivery system. Pharm Dev Technol 2009;14:226-32
101. Mahajan HS, Guttani SG. Nasal administration of ondansetron using a novel microspheres delivery system Part II: ex vivo and vivo studies. Pharm Dev Technol 2010;15:653-71
102. Acarturk F, Celkan A. Comparison of guar gum from different sources for the preparation of prolonged-release or colon-specific dosage forms. Pharm Dev Technol 2009;14:271-7
103. Carmicheal J, Cantwell BM, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with antiemetic response. Cancer Chemother Pharmacol 1989;24:45-9 (Pubitemid 19139989)
104. Woo JS. Nasal absorption studies of granisetron in rats using a validated high-performance liquid chromatographic method with mass spectrometric detection. Arch Pharm Res 2006;30:778-84
105. Cho HJ, Balakrishnan P, Shim WS, et al. Characterization and in vitro evaluation of freeze-dried microparticles composed of granisetron-cyclodextrin complex and carboxymethyl-cellulose for intranasal delivery. Int J Pharm 2010;400:59-65
106. Chaturvedula A, Joshi DP, Anderson CR, et al. Dermal, subdermal, and systemic concentrations of granisetron by iontophoretic delivery. Pharm Res 2005;22:1313-19 (Pubitemid 41176035)
107. Cazares-Delgadillo J, Ganem-Rondero A, Quintanar-Guerrero D, et al. Using transdermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: effect of experimental conditions and a comparison with other enhancement strategies. Eur J Pharm Sci 2010;39:387-93 Available from www.drugdeliverytechonline.com
108. Mahajan H, Shaikh M, Gattani S, et al. In-situ gelling system based on thiolated gellan gum as new carrier for nasal administration of dimenhydrinate. Int J Pharm Sci Nanotechnol 2009;2:544-50
109. Yadav AV, Mote HH. Development of biodegradable starch microspheres for intranasal delivery. Indian J Pharm Sci 2008;70:170-4
110. Hafner A, Filipovic Garcie J. Development and in vitro characterization of chitosan-based microspheres for nasal delivery of promethazine. Drug Dev Ind Pharm 2007;33:427-36 (Pubitemid 46808778)
111. Mcdonough JA, Persyn JT, Nino JA, et al. Microcapsule-gel formulation of promethazine HCI for controlled nasal delivery: a motion sickness medication. J Microencapsul 2007;24:109-16 (Pubitemid 46502154)